Table 1

Patient characteristics

Entire cohort (n = 75)Ig reporter identified (n = 57)No Ig reporter identified (n = 18)P
Average age (years)58.357.560.8.3
Male, n (%)44 (58.7)34 (59.6)10 (55.6).79
Female, n (%)31 (41.3)23 (40.4)8 (44.4)
Diagnosis.23
 DLBCL, NOS543915
 DLBCL, transformed13103
 PTLD880
Stage, n (%).0181
 17 (9.3)7 (12.3)0 (0.0)
 211 (14.7)10 (17.5)1 (5.6)
 38 (10.7)3 (5.3)5 (27.8)
 449 (65.3)37 (64.9)12 (66.7)
IPI, n (%).86
 0 to 113 (18.8)9 (17.6)4 (23.5)
 223 (33.3)17 (33.3)6 (35.3)
 321 (30.4)15 (29.4)6 (35.3)
 4 to 512 (17.4)10 (19.6)2 (11.8)
LDH elevated, n (%)34 (48.6)29 (53.7)5 (31.3).11
Cell of origin
 GCB38 (50.7)27 (47.4)11 (61.1).75
 Non-GCB17 (22.7)13 (22.8)4 (22.2)
 Not available/unclassifiable20 (26.7)17 (29.8)3 (16.7)
Translocations
BCL29/49 (18.4)6/35 (17.1)3/14 (21.4)1
BCL66/41 (14.6)5/29 (17.2)1/12 (8.3).65
MYC8/48 (16.7)6/35 (17.1)2/13 (15.4)1
Treatment
 DA-EPOCH-R22
 R-CHOP like39
 Modified Magrath4
 Other9
 No treatment1
  • Characteristics of all patients enrolled in this study. NOS, not otherwise specified; PTLD, posttransplant lymphoproliferative disorder.